Asep Medical Holdings Inc. (CSE: ASEP) (OTC:SEPSF) – RICH TV LIVE – April 21, 2022 – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce its recent successful listing on the OTCQB Venture Market in the US. The Company will be trading under the stock symbol OTCQB: SEPSF and will continue to sell its common shares on the CSE under the stock symbol CSE: ASEP. Asep Inc. will officially commence trading on the OTCQB as of the market opening today.
Hey guys how you doing this is your boy rich from rich tv live and you too can join the club at richpixdaily.com where you can learn how to win and trade hey guys how you doing this is your boy rich from rich tv live with more exclusive videos for you here and guys you need to join our community our growing community at rich tv dot io where you can learn
About undervalued under-appreciated underexposed opportunities like asep in canada and s-e-p-s-f in america put on your radar put on your watch list we’re talking about a huge growing industry and a major major need with antibiotic failure this could potentially save lives and it is a huge growing sector let’s take a look at it right here right now don’t
Touch that dial so this is right on their website asapmedical.com in their about section asap consolidates two development stage companies sepsit bioscience and abt innovations with shared missions founders and investors our purpose is to mitigate the global crisis of antibiotic failure by improving patients odds of survival and quality of life together i our
Diagnostic and therapeutic solutions represent tremendous clinical and commercial potential through rapid diagnosis and uniquely effective treatment this is the focus of asepmedical.com asep in canada on the canadian securities exchange and s-e-p-s-f in america on the otcqb exchange all right this is asap medical holdings inc fighting antibiotic failure
On two fronts diagnostic and therapeutic diagnostic novel assay provides earlier faster diagnosis and targeted treatment of sepsis and you can learn more right here on the website at asepmedical.com asap on the canadian securities exchange the cse and s-e-p-s-f on the otcqb in america you can also see therapeutic patented pharmaceutical peptide targets
Currently untreatable biofilm infections and you can learn more right at the website at asepmedical.com they’ve also had some big news here you can see asap medical on november 19 2021 announces listing on the canadian securities exchange the cse closing of acquisition of majority interest in abt and sepsis and grant of stock options this is the big news that
They made and then on december 16 2021 asap medical holdings inc announces public listing on the csc to drive the fight against antibiotic failure now i want to show you the stock and the chart you can see here the highs and lows of the chart and it is clearly trading near a low zone you can see it’s been as high as a dollar been as low as 25 cents and currently
Sitting right at around 40 cents so much closer to the low zone so a decent entry point and you can see here in america similar it’s been as high as 33 been as low as 27 and currently sitting right at 32 and a half cents in america essentially just getting started trading in america so you know to get to know the company it’s important to be able to break down
All the specifics and understand the fundamentals and that’s what we do here at rich tv live i must remind you that rich tv live is strictly for information and education purposes please do your due diligence do your research before you invest in anything we talk about or discuss here on rich tv live you can see here asap brings both a novel diagnostic and
Therapeutic approach to the urgent multi-billion dollar problem of antibiotic failure our purpose is to mitigate the global crisis of antibiotic failure by improving patients odds of survival and quality of life you can see here the crisis is a widespread and deadly 49 million a year cases of sepsis 11 million sepsis deaths per year staggering number 100 000
100 percent incidence of sepsis in cova deaths 10 to 100 times more resistant to most antibiotics zero drugs approved for biofilms and 65 of all infections are biofilms you can see here the multi-billion dollar opportunity 41.9 billion global antibiotic market cajr compound annual growth rate of 3 and you can see the 1 billion global sepsis dx cagr compound
Annual growth rate of 8.5 percent so a very large growth market rapid diagnostic test delivers results in one hour improving sepsis survival rates and allowing doctors to make better informed treatment decisions and every hour accounts you can see here with asap patient experience illness and initial infection requiring hospital care er admission clinical
Suspects sepsis based on symptoms blood collection and ideal prognostication sepsis er early diagnostic tests appropriate treatment path and you can see here the discharge and then the conventional therapies which leads to 20 to 30 percent of patients die of sepsis at the bottom of the chart every hour delaying diagnosis and appropriate treatment results
In 7.6 increased probability of death so this is a huge huge concern and problem and a major focus for asep medical you can see diagnostic advantages greater sensitivity and specificity than the sirs sirs systematic inflammatory response syndrome criteria used today earlier recognition of sepsis at a time when patients are admitted to the emergency room
Reliable diagnosis for determining the most appropriate treatments to improve survival and next generation molecular diagnostic focusing on patient specific immune response potent therapeutic technology proprietary peptide technology directly addresses the ineffectiveness of current treatment options by suppressing biofilm growth and reducing inflammation and
You can see here they are attacking the biofilm mrsa biofilm on human skill a human skin our peptide destroys the biofilm bacterial biofilms are very resistant communities that grow on body surfaces you can see the urgent unmet needs and you can see here the most dangerous escape pathogens include untreatable variants and you can see the peptide technology
Highlights anti-biofilm activity anti-bio antibiotic synergy safe and effective in animal infection models anti-inflammatory activity in vivo immune modulating activity and combined activities you can see the initial clinical opportunity chronic crs rhino sinus situs crs crs is a lifelong condition causing painful inflammation due to bacterial biofilm
Infection 242 000 emergency room visits annually antibiotics do not work do not target the biofilm only treat symptoms not the cause thirty thousand dollars a year cost first treatment approved for inadequately controlled crs with poor adoption due to pricing limitations and you can see grant funding molecular diagnostics and peptide therapeutics all funding
Prior to current financing was non-dilutive and largely research grants so you can see the millions in funding thus far very impressive and their intellectual property their diagnostics one patent family plus one underway and three patents awarded and therapeutics three patent families several awarded and 12 filed patents and they are working on patents
For the biomakers have been filed and already awarded in europe china and hong kong in the national phase entry process for canada united states australia japan and europe and you can see here they’re also working with therapeutics in two patents in u.s spain denmark and australia so lots of exciting things happening here including eight patents for small
Catanic anti-microbial peptides eight pence in the u.s spain denmark and australia and we can look here at the share structure obviously very important for us to understand how many shares are issued outstanding for the company 56 million very tightly held 4.5 million warrants and options at 50 cents and fully diluted only 60 million 680 344 shares so very
Tightly held which is something that is extremely important to us here and in understanding the fundamentals you can see here the timeline finalization of 510k submission this is in the diagnostics final clinical violation sorry validation and file for approval strategic partner commercialize commercial launch and therapeutics finalize pre-clea pre-clinical
Development development of ind filing clinical study design and pre-ind meeting and ind approval and investment highlights you can also find all of this information on their website when you scroll down you can see a lot of this information and details are right here on the website as well including investment highlights large addressable global markets novel
Technologies extensive intellectual properties near-term revenue models publicly listed and experienced management team and you can see here their management team from the chairman to the business development officer chief operating officer chief financial officer and chief scientific officer so a team with years and years and years of experience the chairman
And ceo rudy mazzaki over 30 years senior executive management technology and intellectual property development experience founder of over a dozen healthcare companies development and commercialized multiple technologies and deep experience with clinical validation and regulatory reviews so lots of experience with the team and you can see here the board of
Directors so lots of experience as well with the board you can see here the biofilm associated diseases and affected organs the body system affected organs and diseases and the validation studies aseps solutions to crs asap peptides address both biofilm infections and associated inflammation and have demonstrated excellent results in animal models so you
Can see the strong anti-bacterial response and the strong anti-inflammatory response so what are the designation benefits orphan drug designation awardees are granted the following benefits from the fda food and drug administration lower hurdles to approval longer exclusivity lower market costs faster uptake premium pricing favorable reimbursement tax credits
Of 50 of the clinical drug testing cost awarded upon approval eligibility for market exclusivity for seven years post approval and waiver of new drug application nda fee 2.2 million value and acceleration of the development process and advantages post marketing and when you compare them with molecular diagnostics and where they are as far as their revenues
And market cap you can see some of the companies that are currently in clinical indications and phases of development and you can see their revenues and market cap all right love to know what you guys think of this video if you like the video please smash the like button comment down below share the video everywhere and subscribe this is rich from rich tv
Live we love to bring you winners and we love to bring them to you first this is a multi-billion dollar opportunity as sepsis and antibiotic resistant infections continue to be a severe burden on the health care system asap offers excellent investment potential with a combined market of 179 billion and robust growth so you can see here enormous growth potential
And you can learn more and feel free to contact the company right on their website website at asepmedical.com feel free to contact them and they will respond to you with any questions you might have this is rich from rich tv live bringing you asapmedical.com and i’m out
Transcribed from video
Asep Medical Holdings Inc. (CSE: ASEP) (OTC:SEPSF) – RICH TV LIVE By RICH TV LIVE
